Deconstructing breast cancer cell biology and the mechanisms of multidrug resistance

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1846, Issue 2, 2014, Pages 312-325

  Videira, Mafalda ^a   Reis, Rita Leones ^a   Brito, Maria Alexandra ^a  

^a RESEARCH INSTITUTE FOR MEDICINES IMED ULISBOA   (Portugal)

Author keywords

Cancer biology; Chemoresistance; Efflux transporters; Epithelial mesenchymal transition; Multidrug resistance proteins; Tumor microenvironment

Indexed keywords

1,2,3,4,6,7,12,12A OCTAHYDRO 6 ISOBUTYL 9 METHOXY 1,4 DIOXOPYRAZINO[1',2':1,6]PYRIDO[3,4 B]INDOLE 3 PROPANOIC ACID TERT BUTYL ESTER; ABC TRANSPORTER; BREAST CANCER RESISTANCE PROTEIN; CYCLOSPORIN A; ELACRIDAR; FLAVONOID; FUMITREMORGIN C; GEFITINIB; GENISTEIN; IMATINIB; MULTIDRUG RESISTANCE PROTEIN; MYRICETIN; RITONAVIR; SULINDAC; TARIQUIDAR; VALSPODAR; VERAPAMIL; VERLUKAST; ZOSUQUIDAR; TUMOR PROTEIN;

ANGIOGENESIS; BREAST CANCER; BREAST METASTASIS; CANCER CELL; CANCER GROWTH; CARCINOGENESIS; CELL ACTIVITY; CELL FUNCTION; CELL HETEROGENEITY; CELL HYPOXIA; CELL METABOLISM; CELL STRUCTURE; CELL VIABILITY; CYTOLOGY; DNA REPAIR; DNA STRUCTURE; DNA SYNTHESIS INHIBITION; DRUG BINDING; DRUG MECHANISM; DRUG TARGETING; EFFUSION; EPITHELIAL MESENCHYMAL TRANSITION; EXOSOME; EXTRACELLULAR MATRIX; GENE OVEREXPRESSION; HUMAN; NANOMEDICINE; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TUMOR GROWTH; TUMOR MICROENVIRONMENT; BREAST NEOPLASMS; DRUG RESISTANCE; FEMALE; MULTIDRUG RESISTANCE; PATHOLOGY; PHYSIOLOGY; BREAST CANCER CELL LINE; CANCER RESISTANCE; CELL POLARITY; CELL POPULATION; TUMOR INVASION;

BREAST NEOPLASMS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; EXOSOMES; FEMALE; HUMANS; P-GLYCOPROTEIN; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 84906515599     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2014.07.011     Document Type: Review

References (250)

1. Ferlay J., Steliarova-Foucher E., Lortet-Tieulent J., Rosso S., Coebergh J.W., Comber H., Forman D., Bray F. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur. J. Cancer 2013, 49:1374-1403.
2. Blanco E., Ferrari M. Emerging nanotherapeutic strategies in breast cancer. Breast (Edinburgh, Scotland) 2014, 23:10-18.
3. Foulkes W.D., Smith I.E., Reis-Filho J.S. Triple-negative breast cancer. N. Engl. J. Med. 2010, 363:1938-1948.
4. Cadoo K.A., Fornier M.N., Morris P.G. Biological subtypes of breast cancer: current concepts and implications for recurrence patterns. Q. J. Nucl. Med. Mol. Imaging 2013, 57:312-321.
5. Bauer K., Parise C., Caggiano V. Use of ER/PR/HER2 subtypes in conjunction with the 2007St Gallen Consensus Statement for early breast cancer. BMC Cancer 2010, 10:228.
6. Dawson S.J., Rueda O.M., Aparicio S., Caldas C. A new genome-driven integrated classification of breast cancer and its implications. EMBO J. 2013, 32:617-628.
7. Campling B.G., Young L.C., Baer K.A., Lam Y.M., Deeley R.G., Cole S.P., Gerlach J.H. Expression of the MRP and MDR1 multidrug resistance genes in small cell lung cancer. Clin. Cancer Res. 1997, 3:115-122.
8. Allen J.D., Brinkhuis R.F., van Deemter L., Wijnholds J., Schinkel A.H. Extensive contribution of the multidrug transporters P-glycoprotein and Mrp1 to basal drug resistance. Cancer Res. 2000, 60:5761-5766.
9. van Jaarsveld M.T., Wouters M.D., Boersma A.W., Smid M., van Ijcken W.F., Mathijssen R.H., Hoeijmakers J.H., Martens J.W., van Laere S., Wiemer E.A., Pothof J. DNA damage responsive microRNAs misexpressed in human cancer modulate therapy sensitivity. Mol. Oncol. 2014, 8:458-468.
10. Real P.J., Sierra A., De Juan A., Segovia J.C., Lopez-Vega J.M., Fernandez-Luna J.L. Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cells. Oncogene 2002, 21:7611-7618.
11. Iorfida M., Bagnardi V., Rotmensz N., Munzone E., Bonanni B., Viale G., Pruneri G., Mazza M., Cardillo A., Veronesi P., Luini A., Galimberti V., Goldhirsch A., Colleoni M. Outcome of male breast cancer: a matched single-institution series. Clin. Breast Cancer 2014, (Epub ahead of print). 10.1016/j.clbc.2014.02.008.
12. Patel N.R., Pattni B.S., Abouzeid A.H., Torchilin V.P. Nanopreparations to overcome multidrug resistance in cancer. Adv. Drug Deliv. Rev. 2013, 65:1748-1762.
13. Curran C.S., Keely P.J. Breast tumor and stromal cell responses to TGF-beta and hypoxia in matrix deposition. Matrix Biol. 2013, 32:95-105.
14. Weber C.E., Kuo P.C. The tumor microenvironment. Surg. Oncol. 2012, 21:172-177.
15. Zhang B.C., Gao J., Wang J., Rao Z.G., Wang B.C., Gao J.F. Tumor-associated macrophages infiltration is associated with peritumoral lymphangiogenesis and poor prognosis in lung adenocarcinoma. Med. Oncol. 2011, 28:1447-1452.
16. Ham M., Moon A. Inflammatory and microenvironmental factors involved in breast cancer progression. Arch. Pharm. Res. 2013, 36:1419-1431.
17. Leibovich-Rivkin T., Liubomirski Y., Bernstein B., Meshel T., Ben-Baruch A. Inflammatory factors of the tumor microenvironment induce plasticity in nontransformed breast epithelial cells: EMT, invasion, and collapse of normally organized breast textures. Neoplasia 2013, 15:1330-1346.
18. Armulik A., Genove G., Betsholtz C. Pericytes: developmental, physiological, and pathological perspectives, problems, and promises. Dev. Cell 2011, 21:193-215.
19. Sá-Pereira I., Brites D., Brito M.A. Neurovascular unit: a focus on pericytes. Mol. Neurobiol. 2012, 45:327-347.
20. Lu P., Weaver V.M., Werb Z. The extracellular matrix: a dynamic niche in cancer progression. J. Cell Biol. 2012, 196:395-406.
21. Guo X., Wu Y., Hathaway H.J., Hartley R.S. Microenvironmental control of the breast cancer cell cycle. Anat. Rec. (Hoboken) 2012, 295:553-562.
22. Kessenbrock K., Plaks V., Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010, 141:52-67.
23. Kim Y.H., Kwon H.J., Kim D.S. Matrix metalloproteinase 9 (MMP-9)-dependent processing of betaig-h3 protein regulates cell migration, invasion, and adhesion. J. Biol. Chem. 2012, 287:38957-38969.
24. Zhang K., Corsa C.A., Ponik S.M., Prior J.L., Piwnica-Worms D., Eliceiri K.W., Keely P.J., Longmore G.D. The collagen receptor discoidin domain receptor 2 stabilizes SNAIL1 to facilitate breast cancer metastasis. Nat. Cell Biol. 2013, 15:677-687.
25. Kumar S., Das A., Sen S. Extracellular matrix density promotes EMT by weakening cell-cell adhesions. Mol. Biosyst. 2014, 10:838-850.
26. Mayorca-Guiliani A., Erler J. The potential for targeting extracellular LOX proteins in human malignancy. OncoTargets Ther. 2013, 6:1729-1735.
27. Barker H.E., Cox T.R., Erler J.T. The rationale for targeting the LOX family in cancer. Nat. Rev. Cancer 2012, 12:540-552.
28. Keely P.J. Mechanisms by which the extracellular matrix and integrin signaling act to regulate the switch between tumor suppression and tumor promotion. J. Mammary Gland Biol. Neoplasia 2011, 16:205-219.
29. Desgrosellier J.S., Cheresh D.A. Integrins in cancer: biological implications and therapeutic opportunities. Nat. Rev. Cancer 2010, 10:9-22.
30. Chen D., Zhang Y., Zhang X., Li J., Han B., Liu S., Wang L., Ling Y., Mao S., Wang X. Overexpression of integrin-linked kinase correlates with malignant phenotype in non-small cell lung cancer and promotes lung cancer cell invasion and migration via regulating epithelial-mesenchymal transition (EMT)-related genes. Acta Histochem. 2013, 115:128-136.
31. Lum J.J., Bui T., Gruber M., Gordan J.D., DeBerardinis R.J., Covello K.L., Simon M.C., Thompson C.B. The transcription factor HIF-1alpha plays a critical role in the growth factor-dependent regulation of both aerobic and anaerobic glycolysis. Genes Dev. 2007, 21:1037-1049.
32. Kroemer G., Pouyssegur J. Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 2008, 13:472-482.
33. Warburg O. On the origin of cancer cells. Science 1956, 123:309-314.
34. Kamat C.D., Green D.E., Warnke L., Thorpe J.E., Ceriello A., Ihnat M.A. Mutant p53 facilitates pro-angiogenic, hyperproliferative phenotype in response to chronic relative hypoxia. Cancer Lett. 2007, 249:209-219.
35. Kim J.W., Tchernyshyov I., Semenza G.L., Dang C.V. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab. 2006, 3:177-185.
36. Vaupel P., Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev. 2007, 26:225-239.
37. Ryu K., Park C., Lee Y. Hypoxia-inducible factor 1 alpha represses the transcription of the estrogen receptor alpha gene in human breast cancer cells. Biochem. Biophys. Res. Commun. 2011, 407:831-836.
38. Whelan K.A., Schwab L.P., Karakashev S.V., Franchetti L., Johannes G.J., Seagroves T.N., Reginato M.J. The oncogene HER2/neu (ERBB2) requires the hypoxia-inducible factor HIF-1 for mammary tumor growth and anoikis resistance. J. Biol. Chem. 2013, 288:15865-15877.
39. Wong C.C., Gilkes D.M., Zhang H., Chen J., Wei H., Chaturvedi P., Fraley S.I., Wong C.M., Khoo U.S., Ng I.O., Wirtz D., Semenza G.L. Hypoxia-inducible factor 1 is a master regulator of breast cancer metastatic niche formation. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:16369-16374.
40. Choi J.Y., Jang Y.S., Min S.Y., Song J.Y. Overexpression of MMP-9 and HIF-1alpha in breast cancer cells under hypoxic conditions. J. Breast Cancer 2011, 14:88-95.
41. Raghunand N., Gillies R.J. pH and drug resistance in tumors. Drug Resist. Updat. 2000, 3:39-47.
42. Mahoney B.P., Raghunand N., Baggett B., Gillies R.J. Tumor acidity, ion trapping and chemotherapeutics. I. Acid pH affects the distribution of chemotherapeutic agents in vitro. Biochem. Pharmacol. 2003, 66:1207-1218.
43. Martinez-Outschoorn U.E., Lisanti M.P., Sotgia F. Catabolic cancer-associated fibroblasts transfer energy and biomass to anabolic cancer cells, fueling tumor growth. Semin. Cancer Biol. 2014, 25:47-60.
44. Ko Y.H., Lin Z., Flomenberg N., Pestell R.G., Howell A., Sotgia F., Lisanti M.P., Martinez-Outschoorn U.E. Glutamine fuels a vicious cycle of autophagy in the tumor stroma and oxidative mitochondrial metabolism in epithelial cancer cells: implications for preventing chemotherapy resistance. Cancer Biol. Ther. 2011, 12:1085-1097.
45. Banks R., Forbes M., Kinsey S., Stanley A., Ingham E., Walters C., Selby P. Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. Br. J. Cancer 1998, 77:956-964.
46. Hoff P., Machado K. Role of angiogenesis in the pathogenesis of cancer. Cancer Treat. Rev. 2012, 38:825-833.
47. Toi M., Kondo S., Suzuki H., Yamamoto Y., Inada K., Imazawa T., Taniguchi T., Tominaga T. Quantitative analysis of vascular endothelial growth factor in primary breast cancer. Cancer 1996, 77:1101-1106.
48. Geevarghese A., Herman I.M. Pericyte-endothelial crosstalk: implications and opportunities for advanced cellular therapies. Transl. Res. 2014, 163:296-306.
49. Benjamin L.E., Golijanin D., Itin A., Pode D., Keshet E. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J. Clin. Invest. 1999, 103:159-165.
50. De Bock K., Cauwenberghs S., Carmeliet P. Vessel abnormalization: another hallmark of cancer? Molecular mechanisms and therapeutic implications. Curr. Opin. Genet. Dev. 2011, 21:73-79.
51. Jain R.K. Molecular regulation of vessel maturation. Nat. Med. 2003, 9:685-693.
52. Chantrain C.F., Henriet P., Jodele S., Emonard H., Feron O., Courtoy P.J., DeClerck Y.A., Marbaix E. Mechanisms of pericyte recruitment in tumour angiogenesis: a new role for metalloproteinases. Eur. J. Cancer 2006, 42:310-318.
53. Chantrain C.F., Shimada H., Jodele S., Groshen S., Ye W., Shalinsky D.R., Werb Z., Coussens L.M., DeClerck Y.A. Stromal matrix metalloproteinase-9 regulates the vascular architecture in neuroblastoma by promoting pericyte recruitment. Cancer Res. 2004, 64:1675-1686.
54. Mravic M., Asatrian G., Soo C., Lugassy C., Barnhill R.L., Dry S.M., Peault B., James A.W. From pericytes to perivascular tumours: correlation between pathology, stem cell biology, and tissue engineering. Int. Orthop. 2014, (Epub ahead of print).
55. Cooke V.G., LeBleu V.S., Keskin D., Khan Z., O'Connell J.T., Teng Y., Duncan M.B., Xie L., Maeda G., Vong S., Sugimoto H., Rocha R.M., Damascena A., Brentani R.R., Kalluri R. Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway. Cancer Cell 2012, 21:66-81.
56. Kumar A., Nanjunda Swamy S., Sugahara K., Rangappa K.S. Anti-tumor and anti-angiogenic activity of novel hydantoin derivatives: inhibition of VEGF secretion in liver metastatic osteosarcoma cells. Bioorg. Med. Chem. 2009, 17:4928-4934.
57. Crawford Y., Ferrara N. VEGF inhibition: insights from preclinical and clinical studies. Cell Tissue Res. 2009, 335:261-269.
58. Record M., Carayon K., Poirot M., Silvente-Poirot S. Exosomes as new vesicular lipid transporters involved in cell-cell communication and various pathophysiologies. Biochim. Biophys. Acta 2014, 1841:108-120.
59. Riches A., Campbell E., Borger E., Powis S. Regulation of exosome release from mammary epithelial and breast cancer cells - a new regulatory pathway. Eur. J. Cancer 2014, 50:1025-1034.
60. Ratajczak J., Wysoczynski M., Hayek F., Janowska-Wieczorek A., Ratajczak M.Z. Membrane-derived microvesicles: important and underappreciated mediators of cell-to-cell communication. Leukemia 2006, 20:1487-1495.
61. Lee J.K., Park S.R., Jung B.K., Jeon Y.K., Lee Y.S., Kim M.K., Kim Y.G., Jang J.Y., Kim C.W. Exosomes derived from mesenchymal stem cells suppress angiogenesis by down-regulating VEGF expression in breast cancer cells. PLoS One 2013, 8:e84256.
62. Ramani V.C., Purushothaman A., Stewart M.D., Thompson C.A., Vlodavsky I., Au J.L., Sanderson R.D. The heparanase/syndecan-1 axis in cancer: mechanisms and therapies. FEBS J. 2013, 280:2294-2306.
63. Vlassov A.V., Magdaleno S., Setterquist R., Conrad R. Exosomes: current knowledge of their composition, biological functions, and diagnostic and therapeutic potentials. Biochim. Biophys. Acta 2012, 1820:940-948.
64. Blanchard N., Lankar D., Faure F., Regnault A., Dumont C., Raposo G., Hivroz C. TCR activation of human T cells induces the production of exosomes bearing the TCR/CD3/zeta complex. J. Immunol. 2002, 168:3235-3241.
65. O'Brien K., Rani S., Corcoran C., Wallace R., Hughes L., Friel A.M., McDonnell S., Crown J., Radomski M.W., O'Driscoll L. Exosomes from triple-negative breast cancer cells can transfer phenotypic traits representing their cells of origin to secondary cells. Eur. J. Cancer 2013, 49:1845-1859.
66. Hoffman R.M. Stromal-cell and cancer-cell exosomes leading the metastatic exodus for the promised niche. Breast Cancer Res. 2013, 15:310.
67. Luga V., Wrana J.L. Tumor-stroma interaction: revealing fibroblast-secreted exosomes as potent regulators of Wnt-planar cell polarity signaling in cancer metastasis. Cancer Res. 2013, 73:6843-6847.
68. Webber J., Steadman R., Mason M.D., Tabi Z., Clayton A. Cancer exosomes trigger fibroblast to myofibroblast differentiation. Cancer Res. 2010, 70:9621-9630.
69. Hendrix A., Hume A.N. Exosome signaling in mammary gland development and cancer. Int. J. Dev. Biol. 2011, 55:879-887.
70. Papi A., De Carolis S., Bertoni S., Storci G., Sceberras V., Santini D., Ceccarelli C., Taffurelli M., Orlandi M., Bonafe M. PPARgamma and RXR ligands disrupt the inflammatory cross-talk in the hypoxic breast cancer stem cells niche. J. Cell. Physiol. 2014, (Epub ahead of print). 10.1002/jcp.24601.
71. Thiery J.P. Epithelial-mesenchymal transitions in tumour progression. Nat. Rev. Cancer 2002, 2:442-454.
72. Mallini P., Lennard T., Kirby J., Meeson A. Epithelial-to-mesenchymal transition: what is the impact on breast cancer stem cells and drug resistance. Cancer Treat. Rev. 2014, 40:341-348.
73. Mendez M.G., Kojima S., Goldman R.D. Vimentin induces changes in cell shape, motility, and adhesion during the epithelial to mesenchymal transition. FASEB J. 2010, 24:1838-1851.
74. Yang J., Weinberg R.A. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev. Cell 2008, 14:818-829.
75. De Craene B., Berx G. Regulatory networks defining EMT during cancer initiation and progression. Nat. Rev. Cancer 2013, 13:97-110.
76. Vesuna F., van Diest P., Chen J.H., Raman V. Twist is a transcriptional repressor of E-cadherin gene expression in breast cancer. Biochem. Biophys. Res. Commun. 2008, 367:235-241.
77. Tsubaki M., Komai M., Fujimoto S., Itoh T., Imano M., Sakamoto K., Shimaoka H., Takeda T., Ogawa N., Mashimo K., Fujiwara D., Mukai J., Sakaguchi K., Satou T., Nishida S. Activation of NF-kappaB by the RANKL/RANK system up-regulates snail and twist expressions and induces epithelial-to-mesenchymal transition in mammary tumor cell lines. J. Exp. Clin. Cancer Res. 2013, 32:62.
78. Blanco M.J., Moreno-Bueno G., Sarrio D., Locascio A., Cano A., Palacios J., Nieto M.A. Correlation of Snail expression with histological grade and lymph node status in breast carcinomas. Oncogene 2002, 21:3241-3246.
79. Yang J., Mani S.A., Donaher J.L., Ramaswamy S., Itzykson R.A., Come C., Savagner P., Gitelman I., Richardson A., Weinberg R.A. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004, 117:927-939.
80. Grund E.M., Kagan D., Tran C.A., Zeitvogel A., Starzinski-Powitz A., Nataraja S., Palmer S.S. Tumor necrosis factor-alpha regulates inflammatory and mesenchymal responses via mitogen-activated protein kinase kinase, p38, and nuclear factor kappaB in human endometriotic epithelial cells. Mol. Pharmacol. 2008, 73:1394-1404.
81. Maugeri-Sacca M., Zeuner A., De Maria R. Therapeutic targeting of cancer stem cells. Front. Oncol. 2011, 1:10.
82. Campbell L.L., Polyak K. Breast tumor heterogeneity: cancer stem cells or clonal evolution?. Cell Cycle 2007, 6:2332-2338.
83. Lobo N.A., Shimono Y., Qian D., Clarke M.F. The biology of cancer stem cells. Annu. Rev. Cell Dev. Biol. 2007, 23:675-699.
84. Brabletz T., Jung A., Spaderna S., Hlubek F., Kirchner T. Opinion: migrating cancer stem cells - an integrated concept of malignant tumour progression. Nat. Rev. Cancer 2005, 5:744-749.
85. Brabletz T. EMT and MET in metastasis: where are the cancer stem cells?. Cancer Cell 2012, 22:699-701.
86. Morel A.P., Lievre M., Thomas C., Hinkal G., Ansieau S., Puisieux A. Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS One 2008, 3:e2888.
87. Vinogradov S., Wei X. Cancer stem cells and drug resistance: the potential of nanomedicine. Nanomedicine (Lond.) 2012, 7:597-615.
88. Gillham H., Golding M., Pepperkok R., Gullick W. Intracellular movement of green fluorescent protein-tagged phosphatidylinositol 3-kinase in response to growth factor receptor signaling. J. Cell Biol. 1999, 146:869-880.
89. Zhang L., Zhou F., ten Dijke P. Signaling interplay between transforming growth factor-β receptor and PI3K/AKT pathways in cancer. Trends Biochem. Sci. 2013, 38:612-620.
90. Joensuu H., Pylkkanen L., Toikkanen S. Bcl-2 protein expression and long-term survival in breast cancer. Am. J. Pathol. 1994, 145:1191-1198.
91. Bai L., Wang S. Targeting apoptosis pathways for new cancer therapeutics. Annu. Rev. Med. 2014, 65:139-155.
92. Harada H., Itasaka S., Kizaka-Kondoh S., Shibuya K., Morinibu A., Shinomiya K., Hiraoka M. The Akt/mTOR pathway assures the synthesis of HIF-1alpha protein in a glucose- and reoxygenation-dependent manner in irradiated tumors. J. Biol. Chem. 2009, 284:5332-5342.
93. Mimeault M., Batra S.K. Hypoxia-inducing factors as master regulators of stemness properties and altered metabolism of cancer- and metastasis-initiating cells. J. Cell. Mol. Med. 2013, 17:30-54.
94. Phillips R.J., Mestas J., Gharaee-Kermani M., Burdick M.D., Sica A., Belperio J.A., Keane M.P., Strieter R.M. Epidermal growth factor and hypoxia-induced expression of CXC chemokine receptor 4 on non-small cell lung cancer cells is regulated by the phosphatidylinositol 3-kinase/PTEN/AKT/mammalian target of rapamycin signaling pathway and activation of hypoxia inducible factor-1alpha. J. Biol. Chem. 2005, 280:22473-22481.
95. Jiao M., Nan K.J. Activation of PI3 kinase/Akt/HIF-1alpha pathway contributes to hypoxia-induced epithelial-mesenchymal transition and chemoresistance in hepatocellular carcinoma. Int. J. Oncol. 2012, 40:461-468.
96. Chang F., Steelman L., Lee J., Shelton J., Navolanic P., Blalock W., Franklin R., McCubrey J. Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention. Leukemia 2003, 17:1263-1293.
97. Aksamitiene E., Kholodenko B.N., Kolch W., Hoek J.B., Kiyatkin A. PI3K/Akt-sensitive MEK-independent compensatory circuit of ERK activation in ER-positive PI3K-mutant T47D breast cancer cells. Cell. Signal. 2010, 22:1369-1378.
98. Morgensztern D., McLeod H.L. PI3K/Akt/mTOR pathway as a target for cancer therapy. Anti-Cancer Drugs 2005, 16:797-803.
99. Kang S., Bader A.G., Vogt P.K. Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:802-807.
100. Miron A., Varadi M., Carrasco D., Li H., Luongo L., Kim H.J., Park S.Y., Cho E.Y., Lewis G., Kehoe S., Iglehart J.D., Dillon D., Allred D.C., Macconaill L., Gelman R., Polyak K. PIK3CA mutations in in situ and invasive breast carcinomas. Cancer Res. 2010, 70:5674-5678.
101. Miller T.W., Rexer B.N., Garrett J.T., Arteaga C.L. Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer. Breast Cancer Res. 2011, 13:224.
102. Fu X., Osborne C., Schiff R. Biology and therapeutic potential of PI3K signaling in ER+/HER2-negative breast cancer. Breast (Edinburgh, Scotland) 2013, 22(Suppl. 2):8.
103. Li G., Zhang J., Jin K., He K., Zheng Y., Xu X., Wang H., Wang H., Li Z., Yu X., Teng X., Cao J., Teng L. Estrogen receptor-α36 is involved in development of acquired tamoxifen resistance via regulating the growth status switch in breast cancer cells. Mol. Oncol. 2013, 7:611-624.
104. Motoyama K., Kameyama K., Onodera R., Araki N., Hirayama F., Uekama K., Arima H. Involvement of PI3K-Akt-Bad pathway in apoptosis induced by 2,6-di-O-methyl-beta-cyclodextrin, not 2,6-di-O-methyl-alpha-cyclodextrin, through cholesterol depletion from lipid rafts on plasma membranes in cells. Eur. J. Pharm. Sci. 2009, 38:249-261.
105. Stanculescu A., Bembinster L.A., Borgen K., Bergamaschi A., Wiley E., Frasor J. Estrogen promotes breast cancer cell survival in an inhibitor of apoptosis (IAP)-dependent manner. Horm. Cancer 2010, 1:127-135.
106. dos Santos C.R., Domingues G., Matias I., Matos J., Fonseca I., de Almeida J.M., Dias S. LDL-cholesterol signaling induces breast cancer proliferation and invasion. Lipids Health Dis. 2014, 13:16.
107. Graziani S.R., Igreja F.A., Hegg R., Meneghetti C., Brandizzi L.I., Barboza R., Amancio R.F., Pinotti J.A., Maranhao R.C. Uptake of a cholesterol-rich emulsion by breast cancer. Gynecol. Oncol. 2002, 85:493-497.
108. Raghu H., Sodadasu P., Malla R., Gondi C., Estes N., Rao J. Localization of uPAR and MMP-9 in lipid rafts is critical for migration, invasion and angiogenesis in human breast cancer cells. BMC Cancer 2010, 10:647.
109. Donatello S., Babina I., Hazelwood L., Hill A., Nabi I., Hopkins A. Lipid raft association restricts CD44-ezrin interaction and promotion of breast cancer cell migration. Am. J. Pathol. 2012, 181:2172-2187.
110. Milicevic Z., Bajic V., Zivkovic L., Kasapovic J., Andjelkovic U., Spremo-Potparevic B. Identification of p53 and its isoforms in human breast carcinoma cells. ScientificWorldJournal 2014, 2014:618698.
111. Vassilev L.T., Vu B.T., Graves B., Carvajal D., Podlaski F., Filipovic Z., Kong N., Kammlott U., Lukacs C., Klein C., Fotouhi N., Liu E.A. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004, 303:844-848.
112. Saraswathy M., Gong S. Different strategies to overcome multidrug resistance in cancer. Biotechnol. Adv. 2013, 31:1397-1407.
113. Vasiliou V., Vasiliou K., Nebert D.W. Human ATP-binding cassette (ABC) transporter family. Hum. Genomics 2009, 3:281-290.
114. Szakács G., Annereau J.-P., Lababidi S., Shankavaram U., Arciello A., Bussey K., Reinhold W., Guo Y., Kruh G., Reimers M., Weinstein J., Gottesman M. Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. Cancer Cell 2004, 6:129-137.
115. Kirtane A., Kalscheuer S., Panyam J. Exploiting nanotechnology to overcome tumor drug resistance: challenges and opportunities. Adv. Drug Deliv. Rev. 2013, 65:1731-1747.
116. Schinkel A.H., Jonker J.W. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv. Drug Deliv. Rev. 2012, 64:138-153.
117. Sugawara I., Kataoka I., Morishita Y., Hamada H., Tsuruo T., Itoyama S., Mori S. Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRK 16. Cancer Res. 1988, 48:1926-1929.
118. Bernas M.J., Cardoso F.L., Daley S.K., Weinand M.E., Campos A.R., Ferreira A.J., Hoying J.B., Witte M.H., Brites D., Persidsky Y., Ramirez S.H., Brito M.A. Establishment of primary cultures of human brain microvascular endothelial cells to provide an in vitro cellular model of the blood-brain barrier. Nat. Protoc. 2010, 5:1265-1272.
119. Britton K.M., Eyre R., Harvey I.J., Stemke-Hale K., Browell D., Lennard T.W., Meeson A.P. Breast cancer, side population cells and ABCG2 expression. Cancer Lett. 2012, 323:97-105.
120. O'Connor M.L., Xiang D., Shigdar S., Macdonald J., Li Y., Wang T., Pu C., Wang Z., Qiao L., Duan W. Cancer stem cells: a contentious hypothesis now moving forward. Cancer Lett. 2014, 344:180-187.
121. Conze D., Weiss L., Regen P.S., Bhushan A., Weaver D., Johnson P., Rincon M. Autocrine production of interleukin 6 causes multidrug resistance in breast cancer cells. Cancer Res. 2001, 61:8851-8858.
122. Xiang L., Liu Z.H., Huan Q., Su P., Du G.J., Wang Y., Gao P., Zhou G.Y. Hypoxia-inducible factor-2a is associated with ABCG2 expression, histology-grade and Ki67 expression in breast invasive ductal carcinoma. Diagn. Pathol. 2012, 7:32.
123. Leslie E., Deeley R., Cole S. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol. Appl. Pharmacol. 2005, 204:216-237.
124. Juliano R.L., Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta, Biomembr. 1976, 455:152-162.
125. Schinkel A., Kemp S., Dollé M., Rudenko G., Wagenaar E. N-glycosylation and deletion mutants of the human MDR1 P-glycoprotein. J. Biol. Chem. 1993, 268:7474-7481.
126. Aller S., Yu J., Ward A., Weng Y., Chittaboina S., Zhuo R., Harrell P., Trinh Y., Zhang Q., Urbatsch I., Chang G. Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science (New York, N.Y.) 2009, 323:1718-1722.
127. Cardoso F.L., Brites D., Brito M.A. Looking at the blood-brain barrier: molecular anatomy and possible investigation approaches. Brain Res. Rev. 2010, 64:328-363.
128. Aronica E., Gorter J.A., Ramkema M., Redeker S., Özbas-Gerçeker F., Van Vliet E.A., Scheffer G.L., Scheper R.J., Van Der Valk P., Baayen J.C. Expression and cellular distribution of multidrug resistance-related proteins in the hippocampus of patients with mesial temporal lobe epilepsy. Epilepsia 2004, 45:441-451.
129. Brito M.A., Pereira P., Barroso C., Aronica E., Brites D. New autopsy findings in different brain regions of a preterm neonate with kernicterus: neurovascular alterations and up-regulation of efflux transporters. Pediatr. Neurol. 2013, 49:431-438.
130. Sanfilippo O., Ronchi E., De Marco C., Di Fronzo G., Silvestrini R. Expression of P-glycoprotein in breast cancer tissue and in vitro resistance to doxorubicin and vincristine. Eur. J. Cancer 1991, 27:155-158.
131. Van der Bliek A.M., Van der Velde-Koerts T., Ling V., Borst P. Overexpression and amplification of five genes in a multidrug-resistant Chinese hamster ovary cell line. Mol. Cell. Biol. 1986, 6:1671-1678.
132. Nakagawa M., Schneider E., Dixon K.H., Horton J., Kelley K., Morrow C., Cowan K.H. Reduced intracellular drug accumulation in the absence of P-glycoprotein (mdr1) overexpression in mitoxantrone-resistant human MCF-7 breast cancer cells. Cancer Res. 1992, 52:6175-6181.
133. Kartner N., Riordan J.R., Ling V. Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. Science 1983, 221:1285-1288.
134. van Asperen J., van Tellingen O., Tijssen F., Schinkel A.H., Beijnen J.H. Increased accumulation of doxorubicin and doxorubicinol in cardiac tissue of mice lacking mdr1a P-glycoprotein. Br. J. Cancer 1999, 79:108-113.
135. Tsuruo T., Iida H., Tsukagoshi S., Sakurai Y. Potentiation of vincristine and Adriamycin effects in human hemopoietic tumor cell lines by calcium antagonists and calmodulin inhibitors. Cancer Res. 1983, 43:2267-2272.
136. Yusa K., Tsuruo T. Reversal mechanism of multidrug resistance by verapamil: direct binding of verapamil to P-glycoprotein on specific sites and transport of verapamil outward across the plasma membrane of K562/ADM cells. Cancer Res. 1989, 49:5002-5006.
137. Michieli M., Damiani D., Michelutti A., Candoni A., Masolini P., Scaggiante B., Quadrifoglio F., Baccarani M. Restoring uptake and retention of daunorubicin and idarubicin in P170-related multidrug resistance cells by low concentration d-verapamil, cyclosporin-A and SDZ PSC 833. Haematologica 1994, 79:500-507.
138. Nakamura T., Tanaka K., Matsunobu T., Okada T., Nakatani F., Sakimura R., Hanada M., Iwamoto Y. The mechanism of cross-resistance to proteasome inhibitor bortezomib and overcoming resistance in Ewing's family tumor cells. Int. J. Oncol. 2007, 31:803-811.
139. Meister S., Frey B., Lang V.R., Gaipl U.S., Schett G., Schlotzer-Schrehardt U., Voll R.E. Calcium channel blocker verapamil enhances endoplasmic reticulum stress and cell death induced by proteasome inhibition in myeloma cells. Neoplasia 2010, 12:550-561.
140. Saeki T., Ueda K., Tanigawara Y., Hori R., Komano T. Human P-glycoprotein transports cyclosporin A and FK506. J. Biol. Chem. 1993, 268:6077-6080.
141. Shiraga K., Sakaguchi K., Senoh T., Ohta T., Ogawa S., Sawayama T., Mouri H., Fujiwara A., Tsuji T. Modulation of doxorubicin sensitivity by cyclosporine A in hepatocellular carcinoma cells and their doxorubicin-resistant sublines. J. Gastroenterol. Hepatol. 2001, 16:460-466.
142. Li G.Y., Liu J.Z., Zhang B., Wang L.X., Wang C.B., Chen S.G. Cyclosporine diminishes multidrug resistance in K562/ADM cells and improves complete remission in patients with acute myeloid leukemia. Biomed. Pharmacother. 2009, 63:566-570.
143. Dantzig A.H., Shepard R.L., Cao J., Law K.L., Ehlhardt W.J., Baughman T.M., Bumol T.F., Starling J.J. Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. Cancer Res. 1996, 56:4171-4179.
144. Shepard R.L., Cao J., Starling J.J., Dantzig A.H. Modulation of P-glycoprotein but not MRP1- or BCRP-mediated drug resistance by LY335979. Int. J. Cancer 2003, 103:121-125.
145. Fracasso P.M., Goldstein L.J., de Alwis D.P., Rader J.S., Arquette M.A., Goodner S.A., Wright L.P., Fears C.L., Gazak R.J., Andre V.A., Burgess M.F., Slapak C.A., Schellens J.H. Phase I study of docetaxel in combination with the P-glycoprotein inhibitor, zosuquidar, in resistant malignancies. Clin. Cancer Res. 2004, 10:7220-7228.
146. Mistry P., Stewart A.J., Dangerfield W., Okiji S., Liddle C., Bootle D., Plumb J.A., Templeton D., Charlton P. In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576. Cancer Res. 2001, 61:749-758.
147. Pusztai L., Wagner P., Ibrahim N., Rivera E., Theriault R., Booser D., Symmans F.W., Wong F., Blumenschein G., Fleming D.R., Rouzier R., Boniface G., Hortobagyi G.N. Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma. Cancer 2005, 104:682-691.
148. Patel N.R., Rathi A., Mongayt D., Torchilin V.P. Reversal of multidrug resistance by co-delivery of tariquidar (XR9576) and paclitaxel using long-circulating liposomes. Int. J. Pharm. 2011, 416:296-299.
149. Boesch D., Gaveriaux C., Jachez B., Pourtier-Manzanedo A., Bollinger P., Loor F. In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833. Cancer Res. 1991, 51:4226-4233.
150. Fischer V., Rodriguez-Gascon A., Heitz F., Tynes R., Hauck C., Cohen D., Vickers A.E. The multidrug resistance modulator valspodar (PSC 833) is metabolized by human cytochrome P450 3A. Implications for drug-drug interactions and pharmacological activity of the main metabolite. Drug Metab. Dispos. 1998, 26:802-811.
151. Dorr R., Karanes C., Spier C., Grogan T., Greer J., Moore J., Weinberger B., Schiller G., Pearce T., Litchman M., Dalton W., Roe D., List A.F. Phase I/II study of the P-glycoprotein modulator PSC 833 in patients with acute myeloid leukemia. J. Clin. Oncol. 2001, 19:1589-1599.
152. Hyafil F., Vergely C., Vignaud P.Du., Grand-Perret T. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res. 1993, 53:4595-4602.
153. Myer M.S., Joone G., Chasen M.R., van Rensburg C.E. The chemosensitizing potential of GF120918 is independent of the magnitude of P-glycoprotein-mediated resistance to conventional chemotherapeutic agents in a small cell lung cancer line. Oncol. Rep. 1999, 6:217-218.
154. Evers R., Kool M., Smith A.J., van Deemter L., de Haas M., Borst P. Inhibitory effect of the reversal agents V-104, GF120918 and Pluronic L61 on MDR1 Pgp-, MRP1- and MRP2-mediated transport. Br. J. Cancer 2000, 83:366-374.
155. Ahmed-Belkacem A., Pozza A., Munoz-Martinez F., Bates S.E., Castanys S., Gamarro F., Di Pietro A., Perez-Victoria J.M. Flavonoid structure-activity studies identify 6-prenylchrysin and tectochrysin as potent and specific inhibitors of breast cancer resistance protein ABCG2. Cancer Res. 2005, 65:4852-4860.
156. Newman M.J., Rodarte J.C., Benbatoul K.D., Romano S.J., Zhang C., Krane S., Moran E.J., Uyeda R.T., Dixon R., Guns E.S., Mayer L.D. Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance. Cancer Res. 2000, 60:2964-2972.
157. Leslie E.M., Mao Q., Oleschuk C.J., Deeley R.G., Cole S.P. Modulation of multidrug resistance protein 1 (MRP1/ABCC1) transport and ATPase activities by interaction with dietary flavonoids. Mol. Pharmacol. 2001, 59:1171-1180.
158. van Zanden J.J., de Mul A., Wortelboer H.M., Usta M., van Bladeren P.J., Rietjens I.M., Cnubben N.H. Reversal of in vitro cellular MRP1 and MRP2 mediated vincristine resistance by the flavonoid myricetin. Biochem. Pharmacol. 2005, 69:1657-1665.
159. van Zanden J.J., Wortelboer H.M., Bijlsma S., Punt A., Usta M., Bladeren P.J., Rietjens I.M., Cnubben N.H. Quantitative structure activity relationship studies on the flavonoid mediated inhibition of multidrug resistance proteins 1 and 2. Biochem. Pharmacol. 2005, 69:699-708.
160. Schutte M.E., Freidig A.P., van de Sandt J.J., Alink G.M., Rietjens I.M., Groten J.P. An in vitro and in silico study on the flavonoid-mediated modulation of the transport of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) through Caco-2 monolayers. Toxicol. Appl. Pharmacol. 2006, 217:204-215.
161. Schutte M.E., van de Sandt J.J., Alink G.M., Groten J.P., Rietjens I.M. Myricetin stimulates the absorption of the pro-carcinogen PhIP. Cancer Lett. 2006, 231:36-42.
162. Gekeler V., Ise W., Sanders K.H., Ulrich W.R., Beck J. The leukotriene LTD4 receptor antagonist MK571 specifically modulates MRP associated multidrug resistance. Biochem. Biophys. Res. Commun. 1995, 208:345-352.
163. Kok J.W., Veldman R.J., Klappe K., Koning H., Filipeanu C.M., Muller M. Differential expression of sphingolipids in MRP1 overexpressing HT29 cells. Int. J. Cancer 2000, 87:172-178.
164. Pratt S., Shepard R.L., Kandasamy R.A., Johnston P.A., Perry W., Dantzig A.H. The multidrug resistance protein 5 (ABCC5) confers resistance to 5-fluorouracil and transports its monophosphorylated metabolites. Mol. Cancer Ther. 2005, 4:855-863.
165. Morrow C.S., Peklak-Scott C., Bishwokarma B., Kute T.E., Smitherman P.K., Townsend A.J. Multidrug resistance protein 1 (MRP1, ABCC1) mediates resistance to mitoxantrone via glutathione-dependent drug efflux. Mol. Pharmacol. 2006, 69:1499-1505.
166. Matsson P., Pedersen J.M., Norinder U., Bergstrom C.A., Artursson P. Identification of novel specific and general inhibitors of the three major human ATP-binding cassette transporters P-gp, BCRP and MRP2 among registered drugs. Pharm. Res. 2009, 26:1816-1831.
167. Obuchi W., Ohtsuki S., Uchida Y., Ohmine K., Yamori T., Terasaki T. Identification of transporters associated with Etoposide sensitivity of stomach cancer cell lines and methotrexate sensitivity of breast cancer cell lines by quantitative targeted absolute proteomics. Mol. Pharmacol. 2013, 83:490-500.
168. Duffy C.P., Elliott C.J., O'Connor R.A., Heenan M.M., Coyle S., Cleary I.M., Kavanagh K., Verhaegen S., O'Loughlin C.M., NicAmhlaoibh R., Clynes M. Enhancement of chemotherapeutic drug toxicity to human tumour cells in vitro by a subset of non-steroidal anti-inflammatory drugs (NSAIDs). Eur. J. Cancer 1998, 34:1250-1259.
169. O'Connor R., Heenan M., Connolly L., Larkin A., Clynes M. Increased anti-tumour efficacy of doxorubicin when combined with sulindac in a xenograft model of an MRP-1-positive human lung cancer. Anticancer Res. 2004, 24:457-464.
170. O'Connor R., O'Leary M., Ballot J., Collins C.D., Kinsella P., Mager D.E., Arnold R.D., O'Driscoll L., Larkin A., Kennedy S., Fennelly D., Clynes M., Crown J. A phase I clinical and pharmacokinetic study of the multi-drug resistance protein-1 (MRP-1) inhibitor sulindac, in combination with epirubicin in patients with advanced cancer. Cancer Chemother. Pharmacol. 2007, 59:79-87.
171. Gruber B.M., Bubko I., Krzyszton-Russjan J., Anuszewska E.L. Synergistic action of doxorubicin and sulindac in human cervix carcinoma cells - studies on possible mechanisms. Med. Sci. Monit. 2010, 16:BR45-BR51.
172. Brunell D., Sagher D., Kesaraju S., Brot N., Weissbach H. Studies on the metabolism and biological activity of the epimers of sulindac. Drug Metab. Dispos. 2011, 39:1014-1021.
173. Limburg P.J., Mahoney M.R., Ziegler K.L., Sontag S.J., Schoen R.E., Benya R., Lawson M.J., Weinberg D.S., Stoffel E., Chiorean M., Heigh R., Levine J., Della'Zanna G., Rodriguez L., Gostout C., Mandrekar S.J., Smyrk T.C. Randomized phase II trial of sulindac, atorvastatin, and prebiotic dietary fiber for colorectal cancer chemoprevention. Cancer Prev. Res. (Phila.) 2011, 4:259-269.
174. Limburg P.J., Mandrekar S.J., Aubry M.C., Ziegler K.L., Zhang J., Yi J.E., Henry M., Tazelaar H.D., Lam S., McWilliams A., Midthun D.E., Edell E.S., Rickman O.B., Mazzone P., Tockman M., Beamis J.F., Lamb C., Simoff M., Loprinzi C., Szabo E., Jett J. Randomized phase II trial of sulindac for lung cancer chemoprevention. Lung Cancer 2013, 79:254-261.
175. Versantvoort C.H., Broxterman H.J., Lankelma J., Feller N., Pinedo H.M. Competitive inhibition by genistein and ATP dependence of daunorubicin transport in intact MRP overexpressing human small cell lung cancer cells. Biochem. Pharmacol. 1994, 48:1129-1136.
176. Nagasawa K., Natazuka T., Chihara K., Kitazawa F., Tsumura A., Takara K., Nomiyama M., Ohnishi N., Yokoyama T. Transport mechanism of anthracycline derivatives in human leukemia cell lines: uptake and efflux of pirarubicin in HL60 and pirarubicin-resistant HL60 cells. Cancer Chemother. Pharmacol. 1996, 37:297-304.
177. Twentyman P.R., Versantvoort C.H. Experimental modulation of MRP (multidrug resistance-associated protein)-mediated resistance. Eur. J. Cancer 1996, 32A:1002-1009.
178. Versantvoort C.H., Rhodes T., Twentyman P.R. Acceleration of MRP-associated efflux of rhodamine 123 by genistein and related compounds. Br. J. Cancer 1996, 74:1949-1954.
179. Berger W., Elbling L., Hauptmann E., Micksche M. Expression of the multidrug resistance-associated protein (MRP) and chemoresistance of human non-small-cell lung cancer cells. Int. J. Cancer 1997, 73:84-93.
180. Hu M., Krausz K., Chen J., Ge X., Li J., Gelboin H.L., Gonzalez F.J. Identification of CYP1A2 as the main isoform for the phase I hydroxylated metabolism of genistein and a prodrug converting enzyme of methylated isoflavones. Drug Metab. Dispos. 2003, 31:924-931.
181. Perabo F.G., Von Low E.C., Ellinger J., von Rucker A., Muller S.C., Bastian P.J. Soy isoflavone genistein in prevention and treatment of prostate cancer. Prostate Cancer Prostatic Dis. 2008, 11:6-12.
182. Rabindran S.K., Ross D.D., Doyle L.A., Yang W., Greenberger L.M. Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein. Cancer Res. 2000, 60:47-50.
183. Allen J.D., van Loevezijn A., Lakhai J.M., van der Valk M., van Tellingen O., Reid G., Schellens J.H., Koomen G.J., Schinkel A.H. Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. Mol. Cancer Ther. 2002, 1:417-425.
184. Garimella T.S., Ross D.D., Eiseman J.L., Mondick J.T., Joseph E., Nakanishi T., Bates S.E., Bauer K.S. Plasma pharmacokinetics and tissue distribution of the breast cancer resistance protein (BCRP/ABCG2) inhibitor fumitremorgin C in SCID mice bearing T8 tumors. Cancer Chemother. Pharmacol. 2005, 55:101-109.
185. Raaijmakers M.H., de Grouw E.P., Heuver L.H., van der Reijden B.A., Jansen J.H., Scheper R.J., Scheffer G.L., de Witte T.J., Raymakers R.A. Breast cancer resistance protein in drug resistance of primitive CD34+ 38- cells in acute myeloid leukemia. Clin. Cancer Res. 2005, 11:2436-2444.
186. Glavinas H., Kis E., Pal A., Kovacs R., Jani M., Vagi E., Molnar E., Bansaghi S., Kele Z., Janaky T., Bathori G., von Richter O., Koomen G.J., Krajcsi P. ABCG2 (breast cancer resistance protein/mitoxantrone resistance-associated protein) ATPase assay: a useful tool to detect drug-transporter interactions. Drug Metab. Dispos. 2007, 35:1533-1542.
187. Li Y., Hayman E., Plesescu M., Prakash S.R. Synthesis of potent BCRP inhibitor-Ko143. Tetrahedron Lett. 2008, 49:1480-1483.
188. Yanase K., Tsukahara S., Asada S., Ishikawa E., Imai Y., Sugimoto Y. Gefitinib reverses breast cancer resistance protein-mediated drug resistance. Mol. Cancer Ther. 2004, 3:1119-1125.
189. Elkind N.B., Szentpetery Z., Apati A., Ozvegy-Laczka C., Varady G., Ujhelly O., Szabo K., Homolya L., Varadi A., Buday L., Keri G., Nemet K., Sarkadi B. Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, Gefitinib). Cancer Res. 2005, 65:1770-1777.
190. McKillop D., McCormick A.D., Millar A., Miles G.S., Phillips P.J., Hutchison M. Cytochrome P450-dependent metabolism of gefitinib. Xenobiotica 2005, 35:39-50.
191. Leggas M., Panetta J.C., Zhuang Y., Schuetz J.D., Johnston B., Bai F., Sorrentino B., Zhou S., Houghton P.J., Stewart C.F. Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo. Cancer Res. 2006, 66:4802-4807.
192. Kumar G.N., Rodrigues A.D., Buko A.M., Denissen J.F. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J. Pharmacol. Exp. Ther. 1996, 277:423-431.
193. Gupta A., Zhang Y., Unadkat J.D., Mao Q. HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2). J. Pharmacol. Exp. Ther. 2004, 310:334-341.
194. Weiss J., Rose J., Storch C.H., Ketabi-Kiyanvash N., Sauer A., Haefeli W.E., Efferth T. Modulation of human BCRP (ABCG2) activity by anti-HIV drugs. J. Antimicrob. Chemother. 2007, 59:238-245.
195. Burger H., van Tol H., Boersma A.W., Brok M., Wiemer E.A., Stoter G., Nooter K. Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood 2004, 104:2940-2942.
196. Houghton P.J., Germain G.S., Harwood F.C., Schuetz J.D., Stewart C.F., Buchdunger E., Traxler P. Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro. Cancer Res. 2004, 64:2333-2337.
197. Nebot N., Crettol S., d'Esposito F., Tattam B., Hibbs D.E., Murray M. Participation of CYP2C8 and CYP3A4 in the N-demethylation of imatinib in human hepatic microsomes. Br. J. Pharmacol. 2010, 161:1059-1069.
198. Imai Y., Tsukahara S., Asada S., Sugimoto Y. Phytoestrogens/flavonoids reverse breast cancer resistance protein/ABCG2-mediated multidrug resistance. Cancer Res. 2004, 64:4346-4352.
199. Morris M.E., Zhang S. Flavonoid-drug interactions: effects of flavonoids on ABC transporters. Life Sci. 2006, 78:2116-2130.
200. Sergent T., Dupont I., Van der Heiden E., Scippo M.L., Pussemier L., Larondelle Y., Schneider Y.J. CYP1A1 and CYP3A4 modulation by dietary flavonoids in human intestinal Caco-2 cells. Toxicol. Lett. 2009, 191:216-222.
201. Pick A., Muller H., Mayer R., Haenisch B., Pajeva I.K., Weigt M., Bonisch H., Muller C.E., Wiese M. Structure-activity relationships of flavonoids as inhibitors of breast cancer resistance protein. Bioorg. Med. Chem. 2011, 19:2090-2102.
202. Juvale K., Stefan K., Wiese M. Synthesis and biological evaluation of flavones and benzoflavones as inhibitors of BCRP/ABCG2. Eur. J. Med. Chem. 2013, 67:115-126.
203. Lugo M., Sharom F. Interaction of LDS-751 with P-glycoprotein and mapping of the location of the R drug binding site. Biochemistry 2005, 44:643-655.
204. Ruefli A.A., Tainton K.M., Darcy P.K., Smyth M.J., Johnstone R.W. P-glycoprotein inhibits caspase-8 activation but not formation of the death inducing signal complex (disc) following Fas ligation. Cell Death Differ. 2002, 9:1266-1272.
205. Weisburg J.H., Roepe P.D., Dzekunov S., Scheinberg D.A. Intracellular pH and multidrug resistance regulate complement-mediated cytotoxicity of nucleated human cells. J. Biol. Chem. 1999, 274:10877-10888.
206. Chen H., Hao J., Wang L., Li Y. Coexpression of invasive markers (uPA, CD44) and multiple drug-resistance proteins (MDR1, MRP2) is correlated with epithelial ovarian cancer progression. Br. J. Cancer 2009, 101:432-440.
207. Raguz S., Tamburo De Bella M., Tripuraneni G., Slade M.J., Higgins C.F., Coombes R.C., Yague E. Activation of the MDR1 upstream promoter in breast carcinoma as a surrogate for metastatic invasion. Clin. Cancer Res. 2004, 10:2776-2783.
208. Vander Borght S., Komuta M., Libbrecht L., Katoonizadeh A., Aerts R., Dymarkowski S., Verslype C., Nevens F., Roskams T. Expression of multidrug resistance-associated protein 1 in hepatocellular carcinoma is associated with a more aggressive tumour phenotype and may reflect a progenitor cell origin. Liver Int. 2008, 28:1370-1380.
209. Rocco A., Compare D., Liguori E., Cianflone A., Pirozzi G., Tirino V., Bertoni A., Santoriello M., Garbi C., D'Armiento M., Staibano S., Nardone G. MDR1-P-glycoprotein behaves as an oncofetal protein that promotes cell survival in gastric cancer cells. Lab. Invest. 2012, 92:1407-1418.
210. Hui R.C., Gomes A.R., Constantinidou D., Costa J.R., Karadedou C.T., Fernandez de Mattos S., Wymann M.P., Brosens J.J., Schulze A., Lam E.W. The forkhead transcription factor FOXO3a increases phosphoinositide-3 kinase/Akt activity in drug-resistant leukemic cells through induction of PIK3CA expression. Mol. Cell. Biol. 2008, 28:5886-5898.
211. Zhang H., Zhang X., Wu X., Li W., Su P., Cheng H., Xiang L., Gao P., Zhou G. Interference of Frizzled 1 (FZD1) reverses multidrug resistance in breast cancer cells through the Wnt/beta-catenin pathway. Cancer Lett. 2012, 323:106-113.
212. Sims J.T., Ganguly S.S., Bennett H., Friend J.W., Tepe J., Plattner R. Imatinib reverses doxorubicin resistance by affecting activation of STAT3-dependent NF-kappaB and HSP27/p38/AKT pathways and by inhibiting ABCB1. PLoS One 2013, 8:e55509.
213. Zhang F., Zhang H., Wang Z., Yu M., Tian R., Ji W., Yang Y., Niu R. P-glycoprotein associates with Anxa2 and promotes invasion in multidrug resistant breast cancer cells. Biochem. Pharmacol. 2014, 87:292-302.
214. Bebawy M., Combes V., Lee E., Jaiswal R., Gong J., Bonhoure A., Grau G. Membrane microparticles mediate transfer of P-glycoprotein to drug sensitive cancer cells. Leukemia 2009, 23:1643-1649.
215. Gong J., Luk F., Jaiswal R., George A., Grau G., Bebawy M. Microparticle drug sequestration provides a parallel pathway in the acquisition of cancer drug resistance. Eur. J. Pharmacol. 2013, 721:116-125.
216. Vilas-Boas V., Silva R., Nunes C., Reis S., Ferreira L., Vieira C., Carvalho F., Bastos M.d.L., Remião F. Mechanisms of P-gp inhibition and effects on membrane fluidity of a new rifampicin derivative, 1, 8-dibenzoyl-rifampicin. Toxicol. Lett. 2013, 220:259-266.
217. Miyake M., Koyama M., Seno M., Ikeyama S. Identification of the motility-related protein (MRP-1), recognized by monoclonal antibody M31-15, which inhibits cell motility. J. Exp. Med. 1991, 174:1347-1354.
218. Kruh G.D., Belinsky M.G. The MRP family of drug efflux pumps. Oncogene 2003, 22:7537-7552.
219. Sodani K., Patel A., Kathawala R.J., Chen Z.S. Multidrug resistance associated proteins in multidrug resistance. Chin. J. Cancer 2012, 31:58-72.
220. Bera T.K., Iavarone C., Kumar V., Lee S., Lee B., Pastan I. MRP9, an unusual truncated member of the ABC transporter superfamily, is highly expressed in breast cancer. Proc. Natl. Acad. Sci. 2002, 99:6997-7002.
221. Kruh G.D., Guo Y., Hopper-Borge E., Belinsky M.G., Chen Z.S. ABCC10, ABCC11, and ABCC12. Pflugers Arch. 2007, 453:675-684.
222. Malofeeva E.V., Domanitskaya N., Gudima M., Hopper-Borge E.A. Modulation of the ATPase and transport activities of broad-acting multidrug resistance factor ABCC10 (MRP7). Cancer Res. 2012, 72:6457-6467.
223. Rius M., Nies A.T., Hummel-Eisenbeiss J., Jedlitschky G., Keppler D. Cotransport of reduced glutathione with bile salts by MRP4 (ABCC4) localized to the basolateral hepatocyte membrane. Hepatology 2003, 38:374-384.
224. van Aubel R.A., Smeets P.H., Peters J.G., Bindels R.J., Russel F.G. The MRP4/ABCC4 gene encodes a novel apical organic anion transporter in human kidney proximal tubules: putative efflux pump for urinary cAMP and cGMP. J. Am. Soc. Nephrol. 2002, 13:595-603.
225. Nies A., Jedlitschky G., König J., Herold-Mende C., Steiner H., Schmitt H.P., Keppler D. Expression and immunolocalization of the multidrug resistance proteins, MRP1-MRP6 (ABCC1-ABCC6), in human brain. Neuroscience 2004, 129:349-360.
226. Zaman G.J., Lankelma J., van Tellingen O., Beijnen J., Dekker H., Paulusma C., Oude Elferink R.P., Baas F., Borst P. Role of glutathione in the export of compounds from cells by the multidrug-resistance-associated protein. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:7690-7694.
227. Ishikawa T., Ali-Osman F. Glutathione-associated cis-diamminedichloroplatinum (II) metabolism and ATP-dependent efflux from leukemia cells. Molecular characterization of glutathione-platinum complex and its biological significance. J. Biol. Chem. 1993, 268:20116-20125.
228. Nooter K., Brutel de la Riviere G., Look M.P., van Wingerden K.E., Henzen-Logmans S.C., Scheper R.J., Flens M.J., Klijn J.G., Stoter G., Foekens J.A. The prognostic significance of expression of the multidrug resistance-associated protein (MRP) in primary breast cancer. Br. J. Cancer 1997, 76:486-493.
229. Hipfner D.R., Deeley R.G., Cole S.P. Structural, mechanistic and clinical aspects of MRP1. Biochim. Biophys. Acta 1999, 1461:359-376.
230. Partanen L., Staaf J., Tanner M., Tuominen V.J., Borg A., Isola J. Amplification and overexpression of the ABCC3 (MRP3) gene in primary breast cancer. Genes Chromosomes Cancer 2012, 51:832-840.
231. Honorat M., Mesnier A., Vendrell J., Di Pietro A., Lin V., Dumontet C., Cohen P., Payen L. MRP8/ABCC11 expression is regulated by dexamethasone in breast cancer cells and is associated to progesterone receptor status in breast tumors. Int. J. Breast Cancer 2011, 2011:807380.
232. Honorat M., Mesnier A., Vendrell J., Guitton J., Bieche I., Lidereau R., Kruh G.D., Dumontet C., Cohen P., Payen L. ABCC11 expression is regulated by estrogen in MCF7 cells, correlated with estrogen receptor alpha expression in postmenopausal breast tumors and overexpressed in tamoxifen-resistant breast cancer cells. Endocr. Relat. Cancer 2008, 15:125-138.
233. Maliepaard M., Scheffer G.L., Faneyte I.F., van Gastelen M.A., Pijnenborg A.C., Schinkel A.H., van De Vijver M.J., Scheper R.J., Schellens J.H. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res. 2001, 61:3458-3464.
234. Doyle L.A., Yang W., Abruzzo L.V., Krogmann T., Gao Y., Rishi A.K., Ross D.D. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:15665-15670.
235. Litman T., Jensen U., Hansen A., Covitz K.M., Zhan Z., Fetsch P., Abati A., Hansen P.R., Horn T., Skovsgaard T., Bates S.E. Use of peptide antibodies to probe for the mitoxantrone resistance-associated protein MXR/BCRP/ABCP/ABCG2. Biochim. Biophys. Acta 2002, 1565:6-16.
236. Storch C.H., Ehehalt R., Haefeli W.E., Weiss J. Localization of the human breast cancer resistance protein (BCRP/ABCG2) in lipid rafts/caveolae and modulation of its activity by cholesterol in vitro. J. Pharmacol. Exp. Ther. 2007, 323:257-264.
237. Herzog M., Storch C.H., Gut P., Kotlyar D., Fullekrug J., Ehehalt R., Haefeli W.E., Weiss J. Knockdown of caveolin-1 decreases activity of breast cancer resistance protein (BCRP/ABCG2) and increases chemotherapeutic sensitivity. Naunyn Schmiedebergs Arch. Pharmacol. 2011, 383:1-11.
238. Pal A., Mehn D., Molnar E., Gedey S., Meszaros P., Nagy T., Glavinas H., Janaky T., von Richter O., Bathori G., Szente L., Krajcsi P. Cholesterol potentiates ABCG2 activity in a heterologous expression system: improved in vitro model to study function of human ABCG2. J. Pharmacol. Exp. Ther. 2007, 321:1085-1094.
239. Natarajan K., Xie Y., Baer M.R., Ross D.D. Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance. Biochem. Pharmacol. 2012, 83:1084-1103.
240. Ifergan I., Scheffer G.L., Assaraf Y.G. Novel extracellular vesicles mediate an ABCG2-dependent anticancer drug sequestration and resistance. Cancer Res. 2005, 65:10952-10958.
241. Goler-Baron V., Assaraf Y.G. Structure and function of ABCG2-rich extracellular vesicles mediating multidrug resistance. PLoS One 2011, 6:e16007.
242. Zhou S., Liao L., Chen C., Zeng W., Liu S., Su J., Zhao S., Chen M., Kuang Y., Chen X., Li J. CD147 mediates chemoresistance in breast cancer via ABCG2 by affecting its cellular localization and dimerization. Cancer Lett. 2013, 337:285-292.
243. Liu F., Fan D., Qi J., Zhu H., Zhou Y., Yang C., Zhu Z., Xiong D. Co-expression of cytokeratin 8 and breast cancer resistant protein indicates a multifactorial drug-resistant phenotype in human breast cancer cell line. Life Sci. 2008, 83:496-501.
244. Shukla S., Chen Z.S., Ambudkar S.V. Tyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance. Drug Resist. Updat. 2012, 15:70-80.
245. Noguchi K., Katayama K., Sugimoto Y. Human ABC transporter ABCG2/BCRP expression in chemoresistance: basic and clinical perspectives for molecular cancer therapeutics. Pharmgenomics Pers. Med. 2014, 7:53-64.
246. Wang X., Wu X., Wang C., Zhang W., Ouyang Y., Yu Y., He Z. Transcriptional suppression of breast cancer resistance protein (BCRP) by wild-type p53 through the NF-kappaB pathway in MCF-7 cells. FEBS Lett. 2010, 584:3392-3397.
247. Zhang W., Ding W., Chen Y., Feng M., Ouyang Y., Yu Y., He Z. Up-regulation of breast cancer resistance protein plays a role in HER2-mediated chemoresistance through PI3K/Akt and nuclear factor-kappa B signaling pathways in MCF7 breast cancer cells. Acta Biochim. Biophys. Sin. (Shanghai) 2011, 43:647-653.
248. Kiyotani K., Mushiroda T., Imamura C., Hosono N., Tsunoda T., Kubo M., Tanigawara Y., Flockhart D., Desta Z., Skaar T., Aki F., Hirata K., Takatsuka Y., Okazaki M., Ohsumi S., Yamakawa T., Sasa M., Nakamura Y., Zembutsu H. Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. J. Clin. Oncol. 2010, 28:1287-1293.
249. Natarajan K., Bhullar J., Shukla S., Burcu M., Chen Z.S., Ambudkar S.V., Baer M.R. The Pim kinase inhibitor SGI-1776 decreases cell surface expression of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and drug transport by Pim-1-dependent and -independent mechanisms. Biochem. Pharmacol. 2013, 85:514-524.
250. Latorre E., Castiglioni I., Gatto P., Carelli S., Quattrone A., Provenzani A. Loss of protein kinase Cdelta/HuR interaction is necessary to doxorubicin resistance in breast cancer cell lines. J. Pharmacol. Exp. Ther. 2014, 349:99-106.